Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.45 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999430 | 0.94 | OPRM1 (0.49) | OPRM1OPRK1OPRL1ATAD2CHRNB4 | |
| SCHEMBL18019500 | 0.79 | ATAD2 (0.52) | OPRM1OPRK1OPRL1ATAD2NOTUM | |
| SCHEMBL3355838 | 0.77 | CHRM2 (0.47) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL2675331 | 0.76 | ATAD2 (0.52) | OPRM1OPRK1OPRL1ATAD2NOTUM | |
| SCHEMBL31714558 | 0.75 | OPRM1 (0.46) | OPRM1OPRK1OPRL1ATAD2NOTUM | |
| SCHEMBL2554375 | 0.75 | OPRM1 (0.69) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL5116338 | 0.75 | GAA (0.53) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL520157 | 0.74 | TRIM24 (0.49) | ATAD2 | |
| SCHEMBL5114097 | 0.73 | ATAD2 (0.49) | OPRM1OPRK1ATAD2 | |
| SCHEMBL16972849 | 0.73 | NOTUM (0.36) | ATAD2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262056-A1 | Oxindole Oxazolidinones as Antibacterial Agents | PFIZER INC | 2008-10-23 | — | — | US | disclosed |
| EP-1781643-A1 | OXINDOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1781642-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060229348-A1 | Oxindole oxazolidinone as antibacterial agent | JOSYULA VARA PRASAD V N | 2006-10-12 | — | — | US | disclosed |
| WO-2006016221-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006016220-A1 | OXINDOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | LUEHR GARY W | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229348-A1 | Oxindole oxazolidinone as antibacterial agent | OXA1L, MRPL21, RPS27L | OPRM1 293/4885OPRK1 137/4885OPRL1 337/4885 |
| US-20080262056-A1 | Oxindole Oxazolidinones as Antibacterial Agents | OXA1L, OXSR1, OXER1 | OPRM1 200/4885OPRK1 57/4885OPRL1 62/4885 |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | OXA1L, OXSR1, OXER1 | OPRM1 166/4885OPRK1 115/4885OPRL1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.